J.D. Baker. Tradition and toxicity: evidential cultures in the kava safety debate. „Soc Stud Sci”. 41 (3), s. 361–384, 2011. DOI: 10.1177/0306312710395341. PMID: 21879526.
D McDonald. Kava in the Pacific Islands: a contemporary drug of abuse?. „Drug and Alcohol Review”. 19, s. 217–227, 2000. DOI: 10.1080/713659319.
J. Sarris, C. Stough, C.A. Bousman, Z.T. Wahid i inni. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. „J Clin Psychopharmacol”. 33 (5), s. 643–648, 2013. DOI: 10.1097/JCP.0b013e318291be67. PMID: 23635869.
S.C. Narayanapillai, S. Balbo, P. Leitzman, A.E. Grill i inni. Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. „Carcinogenesis”. 35 (10), s. 2365–2372, 2014. DOI: 10.1093/carcin/bgu149. PMID: 25053626.
J. Triolet, A.A. Shaik, D.D. Gallaher, M.G. O’Sullivan i inni. Reduction in colon cancer risk by consumption of kava or kava fractions in carcinogen-treated rats. „Nutr Cancer”. 64 (6), s. 838–846, 2012. DOI: 10.1080/01635581.2012.689917. PMID: 22693990.
Pittler, M. H., Ernst, E. Systematic review: hepatotoxic events associated with herbal medicinal products. „Alimentary Pharmacology & Therapeutics”. 18 (5), s. 451–471, 2003. DOI: 10.1046/j.1365-2036.2003.01689.x. PMID: 12950418.
Sarris, J., Kavanagh, D.J., Byrne, G., Bone, K.M. i inni. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. „Psychopharmacology”. 205 (3), s. 399–407, 2009. DOI: 10.1007/s00213-009-1549-9. PMID: 19430766.
J. Sarris, E. Laporte, A. Scholey, R. King i inni. Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study. „Traffic Inj Prev”. 14 (1), s. 13–17, 2013. DOI: 10.1080/15389588.2012.682233. PMID: 23259514.
dx.doi.org
Michael A.M.A.RuggieroMichael A.M.A. i inni, A Higher Level Classification of All Living Organisms, „PLOS One”, 10 (4), 2015, art. nr e0119248, DOI: 10.1371/journal.pone.0119248, PMID: 25923521, PMCID: PMC4418965 [dostęp 2020-02-20](ang.).
KennyK.KuchtaKennyK., MathiasM.SchmidtMathiasM., AdolfA.NahrstedtAdolfA., German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics, „Planta Medica”, 18, 2015, s. 1647–1653, DOI: 10.1055/s-0035-1558295, ISSN1439-0221, PMID: 26695707 [dostęp 2016-04-23].
Angelique F.A.F.ShowmanAngelique F.A.F. i inni, Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology, „Fitoterapia”, 100, 2015, s. 56–67, DOI: 10.1016/j.fitote.2014.11.012, ISSN1873-6971, PMID: 25464054 [dostęp 2016-04-21].1 stycznia
MarcinM.PosobkiewiczMarcinM., Uchwała 6/2016 [online] [zarchiwizowane z adresu 2017-06-24].
jstor.org
V.V.LebotV.V., J.J.LèvesqueJ.J., The origin and distribution of kava (Piper methysticum Forst. f., Piperaceae): A phytochemical approach, „Allertonia”, 2, 1989, s. 223–281, JSTOR: 23187398 [dostęp 2016-04-23].1 stycznia
Michael A.M.A.RuggieroMichael A.M.A. i inni, A Higher Level Classification of All Living Organisms, „PLOS One”, 10 (4), 2015, art. nr e0119248, DOI: 10.1371/journal.pone.0119248, PMID: 25923521, PMCID: PMC4418965 [dostęp 2020-02-20](ang.).
J.D. Baker. Tradition and toxicity: evidential cultures in the kava safety debate. „Soc Stud Sci”. 41 (3), s. 361–384, 2011. DOI: 10.1177/0306312710395341. PMID: 21879526.
KennyK.KuchtaKennyK., MathiasM.SchmidtMathiasM., AdolfA.NahrstedtAdolfA., German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics, „Planta Medica”, 18, 2015, s. 1647–1653, DOI: 10.1055/s-0035-1558295, ISSN1439-0221, PMID: 26695707 [dostęp 2016-04-23].
J. Sarris, C. Stough, C.A. Bousman, Z.T. Wahid i inni. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. „J Clin Psychopharmacol”. 33 (5), s. 643–648, 2013. DOI: 10.1097/JCP.0b013e318291be67. PMID: 23635869.
G.G. Steiner. The correlation between cancer incidence and kava consumption. „Hawaii Med J”. 59 (11), s. 420–422, 2000. PMID: 11149250.
S.C. Narayanapillai, S. Balbo, P. Leitzman, A.E. Grill i inni. Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. „Carcinogenesis”. 35 (10), s. 2365–2372, 2014. DOI: 10.1093/carcin/bgu149. PMID: 25053626.
J. Triolet, A.A. Shaik, D.D. Gallaher, M.G. O’Sullivan i inni. Reduction in colon cancer risk by consumption of kava or kava fractions in carcinogen-treated rats. „Nutr Cancer”. 64 (6), s. 838–846, 2012. DOI: 10.1080/01635581.2012.689917. PMID: 22693990.
Angelique F.A.F.ShowmanAngelique F.A.F. i inni, Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology, „Fitoterapia”, 100, 2015, s. 56–67, DOI: 10.1016/j.fitote.2014.11.012, ISSN1873-6971, PMID: 25464054 [dostęp 2016-04-21].1 stycznia
Pittler, M. H., Ernst, E. Systematic review: hepatotoxic events associated with herbal medicinal products. „Alimentary Pharmacology & Therapeutics”. 18 (5), s. 451–471, 2003. DOI: 10.1046/j.1365-2036.2003.01689.x. PMID: 12950418.
Sarris, J., Kavanagh, D.J., Byrne, G., Bone, K.M. i inni. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. „Psychopharmacology”. 205 (3), s. 399–407, 2009. DOI: 10.1007/s00213-009-1549-9. PMID: 19430766.
J. Sarris, E. Laporte, A. Scholey, R. King i inni. Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study. „Traffic Inj Prev”. 14 (1), s. 13–17, 2013. DOI: 10.1080/15389588.2012.682233. PMID: 23259514.
KatarzynaK.Zabłocka-SłowińskaKatarzynaK., KatarzynaK.JawnaKatarzynaK., JadwigaJ.BiernatJadwigaJ., [Interactions between synthetic drugs used in treatment of selected central nervous system disorders and dietary supplements and herbal drugs], „Psychiatria Polska”, 47 (3), 2013, s. 487–498, ISSN0033-2674, PMID: 23885542 [dostęp 2018-12-13].
Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz.U. z 2022 r. poz. 1665)
umm.edu
University of Maryland Medical Center: Kava Kava. 2011. [dostęp 2013-10-16]. [zarchiwizowane z tego adresu (2013-05-13)]. (ang.).
MarcinM.PosobkiewiczMarcinM., Uchwała 6/2016 [online] [zarchiwizowane z adresu 2017-06-24].
worldcat.org
GeoffreyG.BurnieGeoffreyG. i inni, Botanica. Ilustrowana, w alfabetycznym układzie, opisuje ponad 10 000 roślin ogrodowych, Niemcy: Könemann, Tandem Verlag GmbH, 2005, ISBN 3-8331-1916-0, OCLC271991134.
KennyK.KuchtaKennyK., MathiasM.SchmidtMathiasM., AdolfA.NahrstedtAdolfA., German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics, „Planta Medica”, 18, 2015, s. 1647–1653, DOI: 10.1055/s-0035-1558295, ISSN1439-0221, PMID: 26695707 [dostęp 2016-04-23].
Angelique F.A.F.ShowmanAngelique F.A.F. i inni, Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology, „Fitoterapia”, 100, 2015, s. 56–67, DOI: 10.1016/j.fitote.2014.11.012, ISSN1873-6971, PMID: 25464054 [dostęp 2016-04-21].1 stycznia
KatarzynaK.Zabłocka-SłowińskaKatarzynaK., KatarzynaK.JawnaKatarzynaK., JadwigaJ.BiernatJadwigaJ., [Interactions between synthetic drugs used in treatment of selected central nervous system disorders and dietary supplements and herbal drugs], „Psychiatria Polska”, 47 (3), 2013, s. 487–498, ISSN0033-2674, PMID: 23885542 [dostęp 2018-12-13].